GlassScriptPhysician profile
Jamie B Lobell
NPI 1164961751
$2,549.97
in general payments reported to CMS, 2019-2025
26 companies · $677 in 2025
The $677 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $444 · 2023: $724 · 2024: $587 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,987.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.71 | 2021-2025 | |
| Lilly USA, LLC | $333.68 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $241.30 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $222.98 | 2023-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $133.36 | 2024-2025 | |
| Corium, LLC | $132.09 | 2023-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $97.24 | 2021-2023 | |
| Abbott Laboratories | $78.87 | 2023-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.10 | 2023-2024 | Trulance, Xifaxan |
| Sanofi-Aventis U.S. LLC | $68.68 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $59.25 | 2023-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $45.90 | 2022 | |
| Merck Sharp & Dohme LLC | $45.02 | 2022-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Xeris Pharmaceuticals, INC. | $38.43 | 2022-2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $31.24 | 2023-2025 | Flumist Quadrivalent, Airsupra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.87 | 2024-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.90 | 2021-2023 | Jardiance |
| Sanofi Pasteur INC. | $25.01 | 2025 | |
| Azurity Pharmaceuticals, INC. | $23.89 | 2023 | Edarbyclor |
| Amarin Pharma, INC. | $20.48 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.53 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $17.48 | 2025 | Ycanth |
| Cranial Technologies, INC | $16.94 | 2025 | Doc Band |
| Novartis Pharmaceuticals Corporation | $15.96 | 2022 | |
| Acadia Pharmaceuticals INC | $15.06 | 2023 | Daybue |
| Genentech USA, INC. | $8.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Lobell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.